Brief: Lisata Therapeutics And Catalent Announce Global Antibody-Drug Conjugate License Agreement
08/10/2025 14:01
Oct 8 (Reuters) - Lisata Therapeutics Inc LSTA.O: LISATA THERAPEUTICS AND CATALENT ANNOUNCE GLOBAL ANTIBODY-DRUG CONJUGATE (ADC) LICENSE AGREEMENT LISATA THERAPEUTICS INC - TO RECEIVE OVER $10 MILLION IN MILESTONE PAYMENTS Source text: ID:nGNX8lvgcF Further company coverage: LSTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal